Big Pharma to Convene & Discuss Accelerating Preclinical Development at Conference, Jan 24-25, 2005, La Jolla CA
LA JOLLA, Calif., Nov. 15 /PRNewswire/ -- Big pharmaceutical companies have integrated plans that are necessary to transition a new chemical entity from non-clinical development to clinical development. The following companies -- Abbott Labs, Biogen Idec, Merck, Novartis, Pfizer are capable of applying cutting-edge approaches in drug metabolism, process chemistry, formulation development, safety assessment, clinical research and regulatory affairs -- to help speed up preclinical timelines in drug development. These methodologies will be shared amongst big pharma and their counterparts -- in the form of presentation and networking, at the upcoming International Preclinical Development Trends & Technologies Conference on January 24-25 2005, La Jolla, announces Strategic Research Institute.
This conference will consist of a well-distinguished faculty coming from industry/academia who will reveal their latest strategies to optimize target identification, lead identification, ADME/Tox and the use of animal models & biomarkers. An afternoon forum on "Translating Science to Business" and "R&D Productivity" is also featured on the agenda, thus provoking the audience to think and discuss about what challenges lie ahead and where the industry needs to be heading in the future.
Highlights of this event will include the following keynote addresses: * "Mouse Model Research for Preclinical Development", Richard P. Woychik, Ph.D., Director, The Jackson Laboratory * "Predicting Drug Disposition", Leslie Z. Benet, Ph.D., Professor in Biopharmaceutical Sciences, University of California San Francisco
Complete list of presenters include: Abbott Laboratories, Biogen Idec, Caprion Pharmaceuticals Inc., DiscoveRx, GVK Biosciences, Iconix Pharmaceuticals, Isis Pharmaceuticals, Merck Research Laboratories, Mouse Specifics Inc., Novartis Pharmaceuticals, Pfizer Global R&D La Jolla, Pfizer Inc., Phylonix Pharmaceuticals, Recombinant Capital, Simulations-Plus Inc., Vitra Bioscience Inc., Xceleron Ltd., National Cancer Institute, National Institutes of Health, The Jackson Laboratory, University of California San Francisco, University of Pennsylvania Medical Center and University of Toronto.
Scientific Advisory Board: - Zahra Parandoosh, Pharm.D., Ph.D., Managing Director, ChemCyte - Rakesh Dixit, Ph.D., DABT, Section Head, Toxicokinetics and Biomarkers Dept., Merck Research Laboratories - Richard M. Eglen, Chief Scientific Officer, DiscoveRx - Wick Johnson, Ph.D., Director, Licensing & Development , Pfizer Inc. - Peter F. Smith, Ph.D., Senior VP, Preclinical Drug Development, Millennium Pharmaceuticals
To receive the full agenda and/or register for the conference, please contact Ed Drilon of Strategic Research Institute at firstname.lastname@example.org or 212-967-0095, x233 (please include name, corporate affiliation, mailing address, and fax number and specify what you are interested in).
For more information on sponsorship & exhibition opportunities, please contact Ed Drilon at email@example.com or at 212-967-0095, x233.
To inquire about becoming a media partner please contact Cheryl Kahan-Radhuber at firstname.lastname@example.org.Strategic Research Institute
CONTACT: Ed Drilon, Strategic Research Institute, +1-212-967-0095,ext. 233, email@example.com
Web site: http://www.srinstitute.com/